Italian pharma Alfasigma is handing $300 million to GSK for an itching treatment the FDA could approve in a couple of weeks.
- Home |
- Italy’s Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
Italy’s Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
- March 9, 2026
Recent Posts
- Oil jumps 5% as Hormuz tanker attacks escalate, US Gulf hurricane shuts in production
- Crescent Energy to acquire Eagle Ford assets from Devon for $4.2 billion
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
